All In Biotech

Drug Trial Radar · NCT01788046

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis

Last checked: Nov 20, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 515 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

515

Actual

Start

Mar 12, 2013

Primary completion

Apr 14, 2014

Study completion May 9, 2014

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.

Conditions

  • Hyperparathyroidism, Secondary

Interventions

  • EtelcalcetideDrug

    Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.

  • PlaceboDrug

    Administered intravenously (IV) three times per week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment PhaseTime frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).

Locations

106 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Azusa, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Chula Vista, California

  • Research Site

    Fairfield, California

  • Research Site

    Glendale, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Norwalk, California

  • Research Site

    Riverside, California

  • Research Site

    Simi Valley, California

  • Research Site

    Denver, Colorado

  • Research Site

    Stamford, Connecticut

  • Research Site

    Lauderdale Lakes, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Macon, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Gurnee, Illinois

  • Research Site

    Merrillville, Indiana

  • Research Site

    Wichita, Kansas

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Bethesda, Maryland

  • Research Site

    Ft. Washington, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Brookhaven, Mississippi

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Eatontown, New Jersey

  • Research Site

    Brooklyn, New York

  • Research Site

    Fresh Meadows, New York

  • Research Site

    Great Neck, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    New Bern, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbia, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Arlington, Texas

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.